Fig. 9.
The depletion of CD8+ T cells in the effector phase reduces tumor protection.
Moreover, depletion of CD4+ T cells in the priming phase results in a significant loss of tumor rejection (P = .02). BALB/c mice (n = 6) were vaccinated according to the immunization protocol outlined in Figure 4. Depletion of T cells was performed with injections of CD8.2 antibody during the effector phase (■, CD8-E) or with CD4.2 antibody during the immunization phase (⋄, CD4-I). Control mice (+) were not pretreated. All mice received an intravenous tumor challenge of 4 × 105 A20 cells. ▪ indicates bsAb.
